MedPath

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

Phase 3
Completed
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Drug: Placebo
Registration Number
NCT00595946
Lead Sponsor
Sucampo Pharma Americas, LLC
Brief Summary

The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with Opioid-induced Bowel Dysfunction.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
439
Inclusion Criteria
  • Consistent treatment for chronic, non-cancer-related pain with any full agonist opioid for at least 30 days prior to screening.
  • Diagnosis of opioid-induced bowel dysfunction (OBD) as confirmed during the screening period.
  • If patient has a history of chronic constipation, condition must have been exacerbated by initiation of opioid treatment.
  • Use of prescribed or Over-the-Counter (OTC) medication that affects gastrointestinal motility (other than opioid therapy) must be discontinued during the study.
  • If treated for clinical depression with Selective serotonin reuptake inhibitor (SSRIs), Serotonin-norepinephrine reuptake inhibitor (SNRIs), or Monoamine oxidase inhibitor (MAO) inhibitors, treatment must have been at a stable dose for at least 30 days prior to screening.
  • Use of laxative and stool softeners (with the exception of approved rescue medications) must be discontinued while on study.
Exclusion Criteria
  • Treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction.
  • Patient has been treated for cancer in the past 5 years (with the exception of localized basal cell, squamous cell skin cancer, or in situ cancer that has been resected).
  • Opioid dose adjustment (+/- 30%), and/or change in opioid agent or route of administration within 30 days of screening.
  • Gastrointestinal or abdominal surgical procedures within 90 days prior to screening.
  • Non-ambulatory patients, or those who are unable to eat/drink, take oral medications, or to hold down oral medications due to vomiting.
  • Female patients of childbearing potential who are unable/unwilling to use protocol-specified method(s) of birth control and/or are pregnant, nursing, or plan to become pregnant or nurse during the study.
  • Prior use of Amitiza, lubiprostone, SPI-0211, or RU-0211.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo0 mcg capsules twice daily (BID)
LubiprostoneLubiprostone24 mcg capsules twice daily (BID)
Primary Outcome Measures
NameTimeMethod
Mean Weekly Spontaneous Bowel Movements at Week 8at Week 8

Spontaneous bowel movements (SBMs) are defined as bowel movements without the aid of drugs.

Secondary Outcome Measures
NameTimeMethod
Mean Number of Spontaneous Bowel Movements (SBM) Per Week Within 12 Weekswithin 12 weeks

Average weekly SBM frequency was calculated from data collected from Week 1 through Week 12

Number of Participants With the First Post-dose Spontaneous Bowel Movement Within 48 Hours Post-dosewithin 48 hours post-dose

The number of participants who experienced their first post-dose Spontaneous Bowel Movement within 24 and 48 hours after dosing started.

Number of Participants Classified as Responderswithin 12 weeks

Number of participants who remained on treatment for at least 8 weeks, and reported at least 3 SBMs for at least half the weeks on study.

Participant Reported Outcome of Treatment Effectivenesswithin 12 weeks

Participants rated treatment effectiveness at the end of each treatment week during the study on a 5-point scale, where 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective. The 12 weekly scores were averaged. Higher scores mean the drug was more effective.

Mean Change From Baseline in Straining, Stool Consistency, Constipation Severity, Abdominal Bloating, Abdominal Discomfort, and Bowel Habit Regularitywithin 12 weeks

Measures collected over 12-week treatment period were averaged, and the score at baseline was subtracted from the score at week 12 to determine the change from baseline.

Straining scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe - higher scores are worse;

Stool consistency scale: 0 = very loose, 1 = loose, 2 = normal, 3 = hard, 4 = very hard (little balls) - middle scores are best;

Constipation severity scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe - higher scores are worse;

Abdominal bloating scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe - higher scores are worse;

Abdominal discomfort scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe - higher scores are worse;

Bowel habit regularity scale: 7-point scale, where 1 = very regular and 7 = very irregular - higher scores are worse

Trial Locations

Locations (93)

Orange County Clinical Trials, Inc.

🇺🇸

Anaheim, California, United States

Apex Medical Research, AMR, Inc.

🇺🇸

Flint, Michigan, United States

Medoff Medical/ Vital re:Search

🇺🇸

Greensboro, North Carolina, United States

Carolina Pharmaceutical Research

🇺🇸

Statesville, North Carolina, United States

Simon Williamson Clinic, PC

🇺🇸

Hueytown, Alabama, United States

Clinical Research Advantage, Inc./ Mesa Family Medical Center

🇺🇸

Mesa, Arizona, United States

Alabama Orthopedic Clinic

🇺🇸

Mobile, Alabama, United States

Verona Clinical Research, Inc.

🇺🇸

Tucson, Arizona, United States

Clinical Research Advantage, Inc.

🇺🇸

Tempe, Arizona, United States

Harmony Clinical Research, Inc.

🇺🇸

Tucson, Arizona, United States

Quality of Life Medical & Research Center, LLC

🇺🇸

Tucson, Arizona, United States

Genova Clinical Research, Inc.

🇺🇸

Tucson, Arizona, United States

Pusch Ridge Family Medicine / WC Clinical Research

🇺🇸

Tucson, Arizona, United States

Advanced Clinical Research Institute

🇺🇸

Anaheim, California, United States

Gregory J. Wiener, MD PC

🇺🇸

Chula Vista, California, United States

Digestive and Liver Disease Specialists

🇺🇸

Norfolk, Virginia, United States

RX Clinical Research, Inc

🇺🇸

Garden Grove, California, United States

Physicians Clinical Research Corporation

🇺🇸

Laguna Hills, California, United States

Loma Linda University Physicians Medical Group

🇺🇸

Loma Linda, California, United States

HealthCare Partners Medical Group

🇺🇸

Long Beach, California, United States

Impact Clinical Trials

🇺🇸

Los Angeles, California, United States

The Regents of the University of California, Los Angeles

🇺🇸

Los Angeles, California, United States

Pasadena Rehabilitation Institute

🇺🇸

Pasadena, California, United States

SB Family Medicine

🇺🇸

Solana Beach, California, United States

Advanced Diagnostic Pain Treatment Center

🇺🇸

New Haven, Connecticut, United States

Lynn Institute of Pueblo

🇺🇸

Pueblo, Colorado, United States

Lynn Institute of the Rockies

🇺🇸

Colorado Springs, Colorado, United States

International Research Clinicians of Conneticut

🇺🇸

Ridgefield, Connecticut, United States

New England Research Associates, LLC

🇺🇸

Trumbull, Connecticut, United States

Century Clinical Research

🇺🇸

Daytona Beach, Florida, United States

Meridien Research

🇺🇸

Brooksville, Florida, United States

South Lake Pain Institute

🇺🇸

Clermont, Florida, United States

International Medical Research

🇺🇸

Daytona Beach, Florida, United States

Clinical Physiology Associates/Clinical Study Center

🇺🇸

Fort Myers, Florida, United States

Southeaster Integrated Medical, PL d/b/a Florida Medical Research Institute

🇺🇸

Gainesville, Florida, United States

Palm Beach Research Center

🇺🇸

West Palm Beach, Florida, United States

North Georgia Premier Research

🇺🇸

Dawsonville, Georgia, United States

Best Clinical Research

🇺🇸

Decatur, Georgia, United States

Drug Studies America

🇺🇸

Marietta, Georgia, United States

Pinnacle Trials Inc.

🇺🇸

Stockbridge, Georgia, United States

Rosemark Women Care Specialists

🇺🇸

Idaho Falls, Idaho, United States

Saltzer Medical Group

🇺🇸

Nampa, Idaho, United States

Millenium Pain Center

🇺🇸

Bloomington, Illinois, United States

University of Illinois Medical Center

🇺🇸

Chicago, Illinois, United States

Redhead Research Inc., dba Research Associates of Central Illinois

🇺🇸

Peoria, Illinois, United States

Integrated Clinical Trial Services, Inc.

🇺🇸

West Des Moines, Iowa, United States

The Pain Treatment Center of the Bluegrass and Ballard Wright, MD PSC

🇺🇸

Lexington, Kentucky, United States

Gulf Coast Research, LLC

🇺🇸

Baton Rouge, Louisiana, United States

Tulane University Health Sciences Center

🇺🇸

New Orleans, Louisiana, United States

The Willis-Knighton Pain Management Center

🇺🇸

Shreveport, Louisiana, United States

Pain and Rehabilitation Medicine

🇺🇸

Bethesda, Maryland, United States

Professional Clinical Research, Benzonia

🇺🇸

Benzonia, Michigan, United States

Center for Clinical Studies

🇺🇸

Dearborn, Michigan, United States

Digestive Health Specialists, PA

🇺🇸

Tupelo, Mississippi, United States

Cooper Health System

🇺🇸

Camden, New Jersey, United States

University of Nevada

🇺🇸

Reno, Nevada, United States

Partners in Primary Care

🇺🇸

Voorhees, New Jersey, United States

Abraham D. Morganoff, MD PA

🇺🇸

Watchung, New Jersey, United States

Northway Medical Associates

🇺🇸

Fulton, New York, United States

Long Island Clinical Research Associates, LLP

🇺🇸

Great Neck, New York, United States

Long Island Gastrointestinal Research Group

🇺🇸

Great Neck, New York, United States

Center for Clinical Research, LLC

🇺🇸

Winston-Salem, North Carolina, United States

Pain Research of Oregon, LLC

🇺🇸

Eugene, Oregon, United States

Private Practice of Dr. Hasan

🇺🇸

Allentown, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Partners in Clinical Research

🇺🇸

Cumberland, Rhode Island, United States

Preferred Primary Care Physicians

🇺🇸

Uniontown, Pennsylvania, United States

Trident Institute of Medical Research, LLC

🇺🇸

North Charleston, South Carolina, United States

University Gastroenterology

🇺🇸

Providence, Rhode Island, United States

Southeastern Clinical Research

🇺🇸

Chattanooga, Tennessee, United States

Comprehensive Pain Specialists, PLLC

🇺🇸

Hendersonville, Tennessee, United States

Integrity Clinical Research, LLC

🇺🇸

Savannah, Tennessee, United States

Bexar Clinical Trials, LLC

🇺🇸

Richardson, Texas, United States

Dallas VA Research Corporation, Inc.

🇺🇸

Dallas, Texas, United States

Salt Lake Research, PLLC

🇺🇸

Salt Lake City, Utah, United States

Permian Research Foundation

🇺🇸

Odessa, Texas, United States

General Clinical Research Center, Virginia Commonwealth University, North Hospital

🇺🇸

Richmond, Virginia, United States

Health Sciences Center

🇨🇦

Hamilton, Ontario, Canada

The Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Impact Clinical Trials, Las Vegas

🇺🇸

Las Vegas, Nevada, United States

Office of Stephen H. Miller, MD

🇺🇸

Las Vegas, Nevada, United States

Diversified Research

🇺🇸

Durham, North Carolina, United States

Vanderbilt University - Interventional Pain Center

🇺🇸

Nashville, Tennessee, United States

St. Alexius Medical Center

🇺🇸

Bismarck, North Dakota, United States

University of Rochester

🇺🇸

Rochester, New York, United States

COR Clinical Research, LLC

🇺🇸

Oklahoma City, Oklahoma, United States

The Birmingham Pain Center

🇺🇸

Birmingham, Alabama, United States

Affinity Research

🇺🇸

Portland, Oregon, United States

Metro Physicians a Division of Wheaton Franciscan Medical Group

🇺🇸

Milwaukee, Wisconsin, United States

Clement J. Zablocki VA Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

UMDNJ

🇺🇸

Stratford, New Jersey, United States

Northern California Research Corporation

🇺🇸

Sacramento, California, United States

© Copyright 2025. All Rights Reserved by MedPath